CytRx Files Long-Delayed Q1 Financials, Named in Ethics Probe over UMass Deal | GenomeWeb

CytRx released this week its long-delayed first-quarter financial results, apparently having settled the accounting issues that had held up the regulatory filing (see RNAi News, 4/23/2004). And while this would seem to be good news for the Los Angeles-based RNAi drug developer, which has seen its stock face delisting while hovering near a 52-week low, it appears that the company is not out of the woods yet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.